MedPath

Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Primary Peritoneal Cavity Cancer
Ovarian Cancer
Registration Number
NCT00087087
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.

Detailed Description

OBJECTIVES:

* Determine the antitumor activity of pemetrexed disodium in patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer that failed higher priority treatment protocols.

* Determine the nature and degree of toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Beginning 7 days before and continuing until 3 weeks after the last dose of pemetrexed disodium, patients also receive oral folic acid daily and cyanocobalamin (vitamin B_12) intramuscularly every 9 weeks.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 11-22 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
51
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Toxicity
Antitumor activity
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (35)

Hinsdale Hematology Oncology Associates

πŸ‡ΊπŸ‡Έ

Hinsdale, Illinois, United States

CCOP - Carle Cancer Center

πŸ‡ΊπŸ‡Έ

Urbana, Illinois, United States

Massachusetts General Hospital Cancer Center

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

West Michigan Cancer Center

πŸ‡ΊπŸ‡Έ

Kalamazoo, Michigan, United States

CCOP - Kalamazoo

πŸ‡ΊπŸ‡Έ

Kalamazoo, Michigan, United States

Ellis Fischel Cancer Center at University of Missouri - Columbia

πŸ‡ΊπŸ‡Έ

Columbia, Missouri, United States

CCOP - Kansas City

πŸ‡ΊπŸ‡Έ

Kansas City, Missouri, United States

CCOP - Cancer Research for the Ozarks

πŸ‡ΊπŸ‡Έ

Springfield, Missouri, United States

St. John's Regional Health Center

πŸ‡ΊπŸ‡Έ

Springfield, Missouri, United States

Hulston Cancer Center at Cox Medical Center South

πŸ‡ΊπŸ‡Έ

Springfield, Missouri, United States

Scroll for more (25 remaining)
Hinsdale Hematology Oncology Associates
πŸ‡ΊπŸ‡ΈHinsdale, Illinois, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.